Company intelligence / Profile preview

AraMed

Not specified, Bavaria, Germanyaramed.ae ↗

Ownership: Private
Development stage: Phase 2

Overview

AraMed GmbH develops, produces, and distributes proven medicinal products with a portfolio focused on emergency and pain medicine. The company also markets new pharmaceutical formats and offers high-quality European cannabis blossoms. Its main concern is to improve therapies in pain management of different origins as well as care in oncology. No specific clinical trial results are disclosed; the company appears to operate primarily with established products rather than novel drug development[1].

Therapeutic areas: OncologyNeurology
Modalities: Small moleculesInjectablesCannabis-based medicines (European cannabis blossoms)
Industry: Biotech

Drug pipeline

4 assets

MB07803

Phase 2

Indications: Type 2 diabetes

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on AraMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AraMed.

Explore the full profile